Suspension of trading
Oncternal Therapeutics, Inc. Stock
Stocks
ONCT
US68236P2065
Biotechnology & Medical Research
|
Delayed
Nasdaq
05:00:00 03/12/2024 HKT
|
5-day change | 1st Jan Change | ||
| 0.5266 USD | -24.11% |
|
-.--% | - |
| 01/07/25 | Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO | CI |
| 01/07/25 | Oncternal Therapeutics, Inc. Announces Management Changes | CI |
| Market Cap | 1.56M 1.34M 1.25M 1.14M 2.15M 149M 2.17M 14.76M 5.76M 74.91M 5.85M 5.72M 248M | P/E 2022 |
-1.19x | P/E 2023 | -0.8x |
|---|---|---|---|---|---|
| Enterprise Value | -32.38M -27.74M -25.95M -23.76M -44.58M -3.1B -45.17M -307M -120M -1.56B -122M -119M -5.15B | EV / Sales 2022 |
-4.9x | EV / Sales 2023 | -2.95x |
| Free-Float |
90.77% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | -24.11% |
| 3 years | 0.53 |  | 13.14 |
| 5 years | 0.53 | | 92.6 |
| 10 years | 0.53 | | 211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Vincent
DFI | Director of Finance/CFO | 63 | 01/04/2017 |
Yisrael Katz
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2023 |
Rajesh Krishnan
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Director | Title | Age | Since |
|---|---|---|---|
David Hale
CHM | Chairman | 77 | 01/12/2018 |
Dan Kisner
BRD | Director/Board Member | 79 | 07/06/2019 |
William LaRue
BRD | Director/Board Member | 75 | 01/12/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 20/6/24 | Free | Director | 2,200 | 0.0743% | ||
| 20/6/24 | Free | Director | 2,200 | 0.0743% | ||
| 20/6/24 | Free | Director | 2,200 | 0.0743% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -24.11% | -.--% | -.--% | -91.71% | 1.56M | |
| +1.09% | +5.26% | +4.44% | +26.03% | 51.22B | |
| -1.72% | +2.10% | +470.15% | +596.32% | 45.38B | |
| +2.24% | +8.60% | +20.19% | +92.42% | 41.97B | |
| +0.61% | +8.99% | +39.13% | +20.33% | 42.15B | |
| -0.93% | -4.80% | +17.39% | +46.60% | 31.95B | |
| +0.21% | +2.78% | - | - | 16.73B | |
| +2.08% | +8.30% | +38.20% | +154.70% | 17.1B | |
| +0.03% | +3.41% | +7.12% | +35.49% | 14.76B | |
| +1.39% | +5.90% | +91.91% | +47.62% | 13.91B | |
| Average | -1.90% | +0.29% | +76.50% | +103.09% | 27.52B | |
| Weighted average by Cap. | +0.45% | +3.13% | +103.13% | +148.78% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 1.49M 1.28M 1.19M 1.09M 2.05M 143M 2.08M 14.11M 5.5M 71.62M 5.59M 5.47M 237M | 785K 672K 629K 576K 1.08M 75.11M 1.1M 7.43M 2.9M 37.73M 2.95M 2.88M 125M |
| Net income | -44.17M -37.84M -35.4M -32.41M -60.82M -4.23B -61.62M -418M -163M -2.12B -166M -162M -7.02B | -39.48M -33.82M -31.64M -28.96M -54.36M -3.78B -55.08M -374M -146M -1.9B -148M -145M -6.28B |
| Net Debt | -63.64M -54.51M -51.01M -46.69M -87.62M -6.09B -88.78M -603M -235M -3.06B -239M -234M -10.12B | -33.94M -29.07M -27.2M -24.9M -46.73M -3.25B -47.35M -321M -125M -1.63B -127M -125M -5.4B |
Employees
29
- Stock Market
- Stocks
- ONCT Stock
Select your edition
All financial news and data tailored to specific country editions
